中等度から重度の化膿性汗腺炎を患う青年を対象とした皮下ソネロキマブの薬物動態と安全性を評価する非盲検単群研究(VELA-TEEN)
活動性の中等度から重度の化膿性汗腺炎を患う研究時点で12歳以上17歳以下の青年を対象とした皮下ソネロキマブの薬物動態と安全性を評価する非盲検単群研究
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arkansas
-
North Little Rock、Arkansas、アメリカ、72117
- Clinical Site
-
-
California
-
Stanford、California、アメリカ、94304
- Clinical Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Clinical Site
-
-
Florida
-
Hollywood、Florida、アメリカ、33201
- Clinical Site
-
Miami、Florida、アメリカ、33136
- Clinical Site
-
-
Georgia
-
Macon、Georgia、アメリカ、31217
- Clinical Site
-
Sandy Springs、Georgia、アメリカ、30328
- Clinical Site
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Clinical Site
-
-
Indiana
-
Columbus、Indiana、アメリカ、47201
- Clinical Site
-
-
Kentucky
-
Murray、Kentucky、アメリカ、42071
- Clinical Site
-
-
Michigan
-
Waterford、Michigan、アメリカ、48328
- Clinical Site
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58103
- Clinical Site
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Clinical Site
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Clinical Site
-
Dallas、Texas、アメリカ、75390-8575
- Clinical Site
-
San Antonio、Texas、アメリカ、78218
- Clinical Site
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23502
- Clinical Site
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Clinical Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
- Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
- Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
- Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
- Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
- Participants with a body weight of ≥ 40 kg.
Exclusion Criteria:
- Participants with a known hypersensitivity to sonelokimab or any of its excipients.
- Participants with a draining fistula count of ≥20 at the Screening Visit.
- Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
- Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
- Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
- Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
- Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:sonelokimab
Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8 |
Open label |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetics (PK) of sonelokimab in adolescents
時間枠:Week 24
|
PK (trough concentrations) of sonelokimab over 24 weeks of treatment |
Week 24
|
|
Adverse events (AEs) following treatment with sonelokimab in adolescents
時間枠:Week 24
|
Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline |
Week 24
|
|
Discontinuation of sonelokimab treatment due to AEs
時間枠:Week 24
|
Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline |
Week 24
|
|
Clinically significant changes in clinical laboratory parameters
時間枠:Week 24
|
Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline |
Week 24
|
|
Clinically significant changes in vital signs
時間枠:Week 24
|
Number of participants with clinically significant changes in vital signs from baseline |
Week 24
|
|
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
時間枠:Week 24
|
Number of participants with clinically significant changes in 12-lead ECG intervals from baseline |
Week 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hidradenitis Suppurativa Clinical Response (HiSCR)75
時間枠:Week 24
|
Percentage of participants achieving a HiSCR75 response over time |
Week 24
|
|
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
時間枠:Week 24
|
Percentage of participants achieving a HiSCR50 response over time |
Week 24
|
|
International Hidradenitis Suppurativa Severity Score System (IHS4)
時間枠:Week 24
|
Absolute change in IHS4 score over time |
Week 24
|
|
Children's Dermatology Life Quality Index (CDLQI)
時間枠:Week 24
|
Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5 |
Week 24
|
|
Numerical Rating Scale (NRS) 30
時間枠:Week 24
|
Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3 |
Week 24
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。